Gene therapy upstarts NightStaRx and Genenta raise venture cash; Syndax pulls an IPO;

@FierceBiotech: Sanofi, Regeneron capture a shot at first-mover advantage in the PCSK9 market. Report | Follow @FierceBiotech

@JohnCFierce: Rockwell's dialysis drug wins an FDA OK, despite lingering doubts. Article | Follow @JohnCFierce

@DamianFierce: Under-rated aspect of $GILD's hep C dominance: correctly spelling "hepatology." More | Follow @DamianFierce

> London-based NightStaRx has banked new venture cash and recruited J&J ($JNJ) veteran David Fellows as its new CEO. The company is developing new gene therapies, with a lead program for Choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Release

> The Milan-based gene therapy biotech Genenta has raised 6 million euros for its R&D work. Story

> Syndax has pulled its $60 million IPO. Story

Medical Device News

@FierceMedDev: ICYMI: Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. Report | Follow @FierceMedDev

@VarunSaxena2: GE Healthcare says strong U.S. growth offset weakness abroad. Story | Follow @VarunSaxena2

@EmilyWFierce: Obama and Narendra Modi scheduled to meet with top U.S. and Indian execs today to discuss business barriers. Story from the WSJ (sub. req.) | Follow @EmilyWFierce

> Study shows ventricular assist devices allow diseased hearts to regenerate muscle. Story

> Neurostim dry eye startup backed by Kleiner Perkins, NEA readies for CE mark. More

> FDA approves first glucose-monitoring app for mobile devices. Article

Pharma News

@FiercePharma: Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Actavis explains the recall of generic Neurontin was limited to 2,000 bottles shipped to one customer. FiercePharmaManufacturing story | Follow @EricPFierce

> Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales. More

> Gilead discounts hep C meds in Germany, offers new-and-improved generics deal in India. News

Biotech IT News

> EMA posts guide to help IT teams with its new pharmacovigilance database. News

> Obama talks up precision meds, cybersecurity in SOTU speech. More

> $4B VC shop lays out its vision for the future of digital health. Story

> GoBalto eyes Asian expansion after $12M Mitsui-led financing. Report

> BIO is preparing small biotechs for life in the social media maelstrom. Article

CRO News

> Trial tech outfit goBalto bags $12M to expand around the world. Report

> PPD beefs up its Irish outpost with a new biologics lab. News

> Australian CRO Novotech firms up its Hong Kong presence. More

> EMA wants more than 700 drugs suspended over GVK data scandal. Story

> Covance pools its early-stage R&D services into one offering. Article

Animal Health News

> Report: Merck said to be testing lower dosage Zilmax to revive sales. More

> Bayer study reveals growth opportunity for vet clinics in fighting parasites. Item

> Valeant CEO quashes rumors of Zoetis buyout bid. Article

> Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. Story

> Report: Livestock research lab prioritizes profits over animal health. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.